@article{JTD60,
author = {Jianxing He and Wenlong Shao and Shuben Li and Manyin Chen and Hanzhang Chen and Jun Liu and Wei Wang and Yuan Qiu and Daoyuan Wang},
title = {Feasibility Of Administering Adjuvant Chemotherapy Of Pemetrexed Followed By Pemetrexed/oxaliplatin Immediately Post -VATS In Patients With Completely Resected NSCLC},
journal = {Journal of Thoracic Disease},
volume = {1},
number = {1},
year = {2011},
keywords = {},
abstract = {Non-small cell lung cancer (NSCLC) accounts for the largest number of cancer deaths annually, worldwide. It seems reasonable to test a less toxic regimen also in early stages after complete (R0) resection of the tumor, where reduced toxicities might improve the feasibility of drug delivery, compliance and the convenience of treatment for the patient and hence perhaps improve survival. The main purpose of this phase II trial is to evaluate the clinical feasibility-in terms of patients without dose limiting toxicities or premature treatment withdrawal or death-of administering adjuvant chemotherapy of pemetrexed followed by pemetrexed/oxaliplatin immediately post-VATS (video-assisted thoracic surgery) in patients with completely resected NSCLC.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/60}
}